PetVivo Q2 FY2023 revenue $223K; net loss $2.1M as Spryng shipments begin to distributor

PetVivo Holdings, Inc.

2024-Q2 EPS reported -$0.41 revenue$281,454

Revenue of $223,280, up from $4,977 YoY, driven by Spryng sales to clinics and distributor MWI.
Net loss of $2.1M ($0.21/share) vs $1.1M ($0.13/share), due to higher operating expenses for commercialization.
Spryng shipments to MWI Animal Health began in Q2; $118,264 revenue from distributor.
Cash and equivalents $2.3M; working capital $2.1M; inventory increased to $304,967.
Accounts opened in 47 states; lead product Spryng for osteoarthritis in dogs/horses.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PetVivo Holdings, Inc. reported the second quarter ended September 30, 2022 results: revenue $223,280, net income $2,111,589, EPS ($0.21) per share.

Period: the second quarter ended September 30, 2022
Revenue: $223,280
Net income: $2,111,589
EPS: ($0.21) per share
Result: reported results

Exact text from the filing

quarter of fiscal year 2023 and recent weeks include the following (all comparisons are with the second quarter of fiscal year 2022, unless otherwise indicated): ● Revenues of $223,280 for the three months ended September 30, 2022, compared to revenues of $4,977 in the three months ended September 30, 2021; ● Net revenue of $118,264 was from shipments of

View on SEC.gov

Browse all earnings releases →

PetVivo Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-031343

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.